COMMUNIQUÉS West-GlobeNewswire

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
08/05/2026
- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application [...]
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
08/05/2026
PMA submission targeted for May 29, 2026 in alignment with FDA Vantive commits to additional funding support ahead of PMA acceptance milestone TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” [...]
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
08/05/2026
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept trial of [...]
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08/05/2026
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
08/05/2026
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this [...]
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
08/05/2026
ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs [...]
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
08/05/2026
Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has issued [...]
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
08/05/2026
Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year Purified Cortrophin ® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year Quarterly GAAP net income available to common [...]
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
08/05/2026
Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no [...]
Profusa Receives Favorable Nasdaq Listing Determination
08/05/2026
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring [...]
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
08/05/2026
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or [...]
ANGEL Expands U.S. Water Purification Lineup with New Whole House Water Filtration Systems
08/05/2026
LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- ANGEL, a global water purification brand, today announced an expanded U.S. lineup of home water systems designed to make everyday water—used for drinking, cooking, and [...]
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
08/05/2026
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for [...]
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
08/05/2026
TOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months [...]
Mobia Medical Announces Pricing of Initial Public Offering
08/05/2026
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI) (“Mobia Medical”), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor [...]
LifeStance Health Group Announces Pricing of Secondary Public Offering
08/05/2026
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
08/05/2026
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids [...]
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
08/05/2026
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and [...]
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/05/2026
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed [...]

Pages